slno: the income statement

MyFinsight

SOLENO THERAPEUTICS INC (SLNO)

For the quarter ending 2025-06-30, SLNO made $32,657K in revenue. -$4,849K in net income. Net profit margin of -14.85%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Total revenue	32,657
Selling, general and administrative	28,238
Research and development	9,147
Cost of goods sold	696
Change in fair value of contingent consideration	1,101
Total operating expenses	39,182
Operating loss	-6,525
Interest income, net	3,193
Interest expense	1,376
Total other income (expense), net	1,817
Net loss	-4,708
Net unrealized loss on marketable securities	-153
Foreign currency translation adjustment	12
Total comprehensive loss	-4,849

Earnings per share, basic	-0.09
Earnings per share, diluted, total	-0.09
Weighted-average common shares outstanding used to calculate basic shares	50,483,281
Weighted-average common shares outstanding used to calculate diluted shares	50,483,281

Unit: Thousand (K) dollars (except for numbers of shares and EPS)